MLH1 and colorectal carcinoma: MSI‐H CRC with MLH1 promoter hypermethylation was more frequent (59/70, 84.3%) in patients with a score ≥6, whereas MSI‐H CRC with unmethylated MLH1 was more frequent (42/51, 82.4%) in those with a score ≤ 5 (P < 0.001) (Table 6).